France Investigation

Fatal drugs trial: what the French authorities are hiding

On January 17th, 2016, a volunteer died after taking part in a drugs trial in the west of France, while four others suffered suspected brain damage. The company who conducted the trial and supervisory authorities have insisted that the tragedy was “unprecedented” and could not have been foreseen. However, new evidence has emerged that a volunteer in a earlier trial with the same drug suffered side effects and that a later MRI scan shows he suffered a stroke. Yet this information appears to have been concealed by the medical and health authorities. Mediapart's science correspondent Michel de Pracontal reports.

Reading articles is for subscribers only. Login

New information casts doubt on the official versions of events surrounding the death of a 49-year-old man from west France during the clinical trial of a drug earlier this year. Guillaume Molinet died on January 17th, 2016, after taking part in the trial carried out by Rennes-based French company Biotrial on behalf of Portuguese pharmaceutical company Bial. Four other volunteers involved in the testing of drug BIA 10-2474 also suffered lesions to the brain.

1€ for 15 days

Can be canceled online at any time

I subscribe

Only our readers can buy us

Support a 100% independent newspaper: without subsidies, without advertising, without shareholders

Get your information from a trusted source

Get exclusive access to revelations from an investigative journal

Already subscribed ?

Forgot password ?

#FREEMORTAZA

Since January 7, 2023 our colleague and friend Mortaza Behboudi has been imprisoned in Afghanistan, in the Taliban prisons.

We do not forget him and call for his release.

Learn more about #FREEMORTAZA

Today on Mediapart

See Journal’s homepage

#FREEMORTAZA

Since January 7, 2023 our colleague and friend Mortaza Behboudi has been imprisoned in Afghanistan, in the Taliban prisons.

We do not forget him and call for his release.

Learn more about #FREEMORTAZA